News

The CASPIAN trial met the primary endpoint of OS in June 2019, reducing the risk of death by 27% (based on a hazard ratio [HR] of 0.73; 95% confidence

The approval for the Tecentriq, Avastin combination is for unresectable or metastatic HCC patients who did not receive prior systemic therapy. Both the drugs, which already have approvals

Nimacimab is a negative-allosteric modulating antibody targeting the cannabinoid 1 (CB1) receptor, which has a known association in renal fibrosis and inflammation. Bird Rock Bio owns the worldwide

The REMDACTA is a two-armed global phase III, randomised, double-blind and multicentre study designed to assess the safety and efficacy of Actemra/RoActemra plus the investigational antiviral remdesivir against

As per the terms of the deal, Arcus Biosciences, which is a California-based oncology-focused biopharma company, will get a payment of $375m upon closing from Gilead Sciences. This

With the EC marketing authorization, Zeposia, an oral medication taken once daily, becomes the only approved sphingosine-1-phosphate (S1P) receptor modulator for RRMS patients with active disease. The approval

If approval is obtained, it would make Nucala the first targeted biologic treatment for patients with this rare and life-threatening disease caused by eosinophilic inflammation. Treatment options are

The multi-centre, randomised, double-blind and parallel-group clinical study will evaluate the efficacy and safety of once-weekly subcutaneous injections of PB1046 in hospitalised Covid-19 patients at high risk for

The therapy is approved for patients with squamous or non-squamous disease and regardless of PD-L1 expression. This application was reviewed under the FDA’s Real-Time Oncology Review (RTOR) pilot